Sun Pharma has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa for the treatment of adults with inadequately controlled Type 2 Diabetes (T2D) mellitus as an adjunct to diet and exercise.

The company plans to launch the product in the market in the coming days. It will be available as a pre-filled, multi-dose injectable pen in 2 strengths (2 mg/1.5 mL and 4 mg/3 mL) that allow flexible, once-weekly dosing.

Aalok Shanghvi, Chief Operating Officer (COO), Sun Pharma, said, “South Africa is the second market after India where Sun Pharma has received approval for generic semaglutide. This reflects our ability to develop complex generic medicines that meet the stringent quality standards across different markets. We remain committed to improving access to generics and making evidence-based treatment options available to patients and healthcare professionals."

South Africa faces a growing burden of T2D, driven in part by rapid urbanisation and changing lifestyles. This rising prevalence places significant pressure on patients and healthcare services. Improving access to effective therapies is therefore an important component of addressing this national health challenge.